Bristol Myers' Opdivo notches a double win against chemo in esophageal cancer, potentially setting up 1st-line nod

Bristol Myers Squibb is one of a group of drugmakers prepping for a tense FDA adcomm later this month to review a host of accelerated approvals. Looking to start the month on the right note, the drugmaker rolled out new data for its PD-(L)1 checkpoint inhibitor Opdivo showing more promise in esophageal cancer.